乙型肝炎病毒包膜M蛋白的高效表达和分离纯化

从病人血清中经过聚合酶链反应扩增得到了编码HBV-M蛋白的基因片段(PreS2+S),将其转入原核表达载体pET-His,构建了原核表达质粒pET-His-M。重组质粒转化大肠杆菌BL21,IPTG诱导表达,收获菌体超声波破碎后,蔗糖梯度溶液洗脱杂质。HBV-M在原核系统中高效表达,分子量为30kD,纯化后得到了纯度为98%的HBV-M蛋白,ELISA检测结构表明M蛋白的抗原性比S蛋白的抗原性强。该研究为进一步研究HBV包膜M蛋白的结构、功能及新型乙肝疫苗的研制奠定了基础。     

转基因作物pat蛋白的双抗体夹心酶联免疫检测方法研究

将克隆到的pat基因构建原核表达载体pET30(+)-pat并在大肠杆菌中进行表达,分离纯化得到高纯度pat蛋白。用所得到的pat蛋白制备了兔多克隆抗体和鼠单抗2F6。多抗效价>8000,单抗效价为5×104;单抗为IgG1类,轻链为κ型。基于抗pat蛋白单克隆抗体和兔多克隆抗体建立了双抗夹心酶联免疫分析方法(Sandwich ELISA)。检测范围为1.6~100μg/L,线性回归方程y=0.6914x-2.572,决定系数为0.9951。用所建立的方法测定了5个转基因抗虫棉和2个非转基因棉花品种叶片中pat蛋白的含量,其中转基因抗虫棉中的3个品种检测出pat蛋白,其余均未检出pat蛋白。     

肠道病毒71型外壳蛋白VP1在大肠杆菌中的表达

将扩增得到的肠道病毒71型外壳蛋白VP1基因克隆到测序载体pGEM-T,测序验证该序列为目的片段后,将目的基因克隆到原核表达载体pGEX-5x-1中,转化大肠杆菌BL21,IPTG诱导表达,产物经SDS-PAGE分析和Western blot验证。结果表明,在经IPTG诱导的BL21中检测到分子量与预期大小相符的大约60 kDa的融合蛋白。利用表达产物作为抗原,对EV71感染病人阳性血清的检测初步证实,重组蛋白VP1可以作为检测EV71感染的检测用抗原。     

重组人OCIF结构域D1～D6基因在毕赤酵母中的表达

利用PCR以实验室构建的原核重组表达质粒pProEX-OCIF为模板扩增得到N末端融合有6×His标签和rTEV蛋白酶识别序列的人破骨细胞形成抑制因子(OsteoclastogenesisInhibitoryFactor,简称OCIF)结构域D1～D6(简称O CIFm)编码基因片段;将其与pMD18-T连接,转化大肠杆菌TOP10,筛选得到阳性重组质粒pMD18-OCIFm,双酶切重组克隆质粒pMD18-OCIFm得到OCIFm基因片段;将其定向插入甲醇营养型酵母分泌表达载体pPIC9中,构建获得重组表达质粒pPIC9-OCIFm.测序验证后,以限制性内切酶SalⅠ线化,电穿孔转化酵母宿主菌GS115.筛选得到阳性表达菌株后,甲醇诱导表达4d,SDS-PAGE和Westernblot对表达情况进行分析和确认.所获得的OCIFm基因片段在甲醇营养型酵母中表达量占菌体总蛋白的30%以上.利用Ni-NTA树脂对表达产物进行一步亲和层析纯化.活性测定表明纯化的表达产物可诱导体外培养的成熟破骨细胞样细胞的凋亡.表达产物的生物学活性较利用原核表达系统明显提高.     

粘着斑激酶的原核表达、纯化及抗体的制备

粘着斑激酶(focal adhesion kinase,FAK)是细胞质内单亚基非受体型酪氨酸激酶,通过各种信号途径参与调节细胞生长、发育、黏附、细胞骨架重组、转化、扩散和迁移等过程.采用PCR方法,从Flag-FAK质粒中克隆编码FAK C端273个氨基酸的基因片段,构建FAK融合蛋白原核表达载体pET28a( )/FAK,进行原核表达与蛋白纯化,取纯化的FAK蛋白免疫小鼠,制备FAK抗血清.结果表明构建的表达FAK C端功能结构域的原核表达质粒pET28a( )/FAK,经过BL21(DE3)大肠杆菌表达、镍亲和层析柱纯化,获得相对分子质量约33 kDa的融合蛋白,并利用小鼠制备了多克隆抗体,EL ISA检测显示该抗体有较高效价.荧光免疫结果显示此多克隆抗体与FAK蛋白特异性结合,为进一步研究神经细胞中FAK的作用机制奠定了基础.     

带肝细胞受体结合区的乙型肝炎病毒表面抗原蛋白性质的研究——形成表面抗原颗粒和在不同细胞中的分泌

我们用定向缺失突变和体外重组法构建了含有肝细胞受体结合区的乙型肝炎病毒(HBV)表面抗原主蛋白(S蛋白)基因。该基因在猴肾细胞COS-M6中的表达产物(S309蛋白)能形成表面抗原(HBsAg)颗粒并分泌出细胞。它在细胞和培养液中稳定,并能分别被抗HBsAg和抗preSl区的抗血清所沉淀。CsCl密度梯度分析显示S309蛋白形成颗粒的密度比S蛋白略大(1.25g/ml)。S309蛋白在肝癌细胞株中容易分泌,分泌量和S蛋白相近。但它在COS-M6细胞中的分泌和肝细胞株相差悬殊,分泌量只有10％左右,而且在培养液中出现较迟。和S蛋白的同时表达则能明显地提高它的分泌效率。     

新型抗HIV-1蛋白GRFT的构建、表达及活性研究

根据已知的新型抗HIV-1蛋白GRFT基因氨基酸序列,推测其DNA编码序列,密码子优化及修饰后进行全基因化学合成,连接到原核表达载体pET28a（+）中,转化大肠杆菌BL21(DE3),IPTG诱导表达,获得目的蛋白. SDS-PAGE、Western Blot分析结果表明,目的蛋白得到良好表达并具有抗原活性;对表达条件进行优化,在最佳表达条件下,目的蛋白的表达量可占菌体总蛋白的55.84%;利用Ni2+-NTA柱亲和层析法进行目的蛋白的复性和纯化,凝胶成像系统扫描分析表明,纯度可达94.06%;运用Dot-ELISA法进行复性蛋白的抗原结合活性检测,结果显示,目的蛋白能够与HIV-1膜蛋白抗原特异性结合,初步证明所表达的重组蛋白具有良好的体外结合活性;基于制备的能够表达HIV-1 gp120基因的靶细胞模型,运用IFA法开展目的蛋白的细胞结合活性研究,结果显示,目的蛋白能够与靶细胞发生特异性反应,表明成功制备并获得了具有生物活性的新型抗HIV-1蛋白GRFT,为进一步研制新型抗HIV-1基因工程药物及其靶向治疗制剂奠定了坚实基础.     

人野生型MBL基因在大肠杆菌中的表达

为获得人MBL蛋白，并对其功能进行初步研究，用DNA重组法构建了组氨到标签融合原核表达质粒pET28(b)-MBL。将重组质粒转入大肠杆菌BL21（DE3），经IPTG在37℃条件下诱导培养，利用SDS－PAGE，Westem-blot检测目的蛋白的表达，用IMAC金属螯合层析柱对其进行纯化。成功地表达了重组MBL蛋白，纯化的MBL浓度约为844μg/mL，为制备MBL的基因工程抗体奠定了基础。     

定点突变提高IL-4免疫毒素对淋巴瘤的选择性和杀伤活性

采用软件分析选择与IL-4分子结合与活性相关的重要位点13T,121R,通过定点突变得到IL-4突变基因cpIL4(13D121E),将其与绿脓杆菌外毒素突变基因PE38KDEL融合,成功地构建了编码免疫毒素cpIL4(13D121E)-PE38KDEL的融合基因.该基因在原核表达系统中得到了高效表达,表达量占细胞全蛋白的30%以上.表达产物经亲和色谱和阴离子交换色谱纯化后,进行细胞毒性实验,证明其对表达型IL-4受体的淋巴瘤细胞Daudi具有良好的细胞毒作用,活性是同类型IL-4免疫毒素的2倍,而对表达型IL-4受体的内皮细胞活性较低.     

HIV-1嵌合抗原的纯化及免疫原性分析

为获得高效的HIV诊断试剂,选定HIV-1的外膜蛋白env中469-511aa,538-674aa和700-734aa3处包含较多抗原位点的区域作为免疫抗原,用PCR的方法从HIV-1全基因扩增编码这3处片段的基因序列,将它们克隆到原核表达载体中,利用大肠杆菌表达系统表达嵌合蛋白.结果发现,3段嵌合基因能在大肠杆菌BL21(Star)中表达,通过Ni-sepharose4B金属Ni螯合层析柱分离纯化目的产物,酶联免疫检测结果表明,纯化抗原有较强的抗原特异性.     

Immunochemical Study of Antigenic Determinants of Recombinant HBsAg Produced by Bombyx mori Larvae

Antibodies to various protein fractions isolated from larvae of mulberry silkworm containing recombinant HBsAg, to plasma HBV, and to healthy human serum were obtained. The cross reactivity of the antibodies was studied using enzyme-linked immunosorbent assay (ELISA). The antigenic determinants of recombinant HBsAg are identical to those in plasma and have practically no common antigenic determinants with healthy human blood serum     

In vivo hepatitis B virus-neutralizing activity of an anti-HBsAg humanized antibody in chimpanzees

Previously, we constructed a humanized antibody (HuS10) that binds to the common a antigenic determinant on the S protein of HBV. In this study, we evaluated its HBV-neutralizing activity in chimpanzees. A study chimpanzee was intravenously administered with a single dose of HuS10, followed by intravenous challenge with the adr subtype of HBV, while a control chimpanzee was only challenged with the virus. The result showed that the control chimpanzee was infected by the virus, and thus serum HBV surface antigen (HBsAg) became positive from the 14(th) to 20(th) week and actively acquired serum anti-HBc and anti-HBs antibodies appeared from the 19(th) and 23(rd) week, respectively. However, in the case of the study chimpanzee, serum HBsAg became positive from the 34(th) to 37(th) week, while actively acquired serum anti-HBc and anti-HBs antibodies appeared from the 37(th) and 40(th) week, respectively, indicating that HuS10 neutralized the virus in vivo and thus delayed the HBV infection. This novel humanized antibody will be useful in the immunoprophylaxis of HBV infection.     

The Properties of an HBV Surface Antigen Protein Carrying the Binding Site for the Receptor of Hepatocytes——Its Formation of Surface Antigen Particles and Secretion From Discrete Cell Lines

A human hepatitis B virus (HBV) gene, which encodes the major surface antigen protein(S protein) carrying the hepatocyte receptor-binding site, was constructed with site-directed mutagenesis and in vitro recombination. When expressed in monkey kidney cell line COS-M6, this gene product (S309 protein) formed surface antigen (HBsAg) particles and secreted from the cells. It was stable within the cells and in the culture medium and could be immunoprecipitated with antisera directed against plasma-derived HBsAg or synthetic preS1 polypeptide. Isopycnic CsCl gradient centrifugation showed that the density of S309 protein particles (1.25 g/ml) was slightly higher than that of S protein particles. The S309 protein was readily secretable from hepatoma cell lines, and the amount secreted was comparable to that of the S protein. By contrast, only about 10% of the S309 protein was secreted from COS-M6 cells, and its appearance in culture medium was delayed. The efficiency of the secretion of the S309 protein can b     

Photochemically inactivated hepatitis B virus promotes upregulation of Th1-type cytokines

Photochemical virus inactivation technology is widely used to improve the safety of blood products. However, the process by which this inactivation occurs and the resulting immunogenicity of treated viruses remain to be elucidated. This study aimed to explore the effects of two photochemical inactivation methods (methylene and riboflavin, MP and RP) on hepatitis B virus (HBV) immunogenicity. Inactivated HBV were incubated with PBMC from six healthy donors. Culture supernatants were collected at 0, 24 and 72 h for the analysis of HBsAg and HBeAg expression using ELISA. Cytokine expression was analyzed at 72 h using ELISA. Costimulatory and cell adhesion molecule mRNA expression was analyzed at 24 h by RT–PCR. No significant changes in HBsAg and HBeAg were detected following MP. However, the secretion of TNF‐α and IFN‐γ was upregulated. Expression of CD80, CD86, ICAM2 and LFA3 mRNA was also upregulated. In contrast, although RP did not significantly alter HBsAg expression, a reduction in HBeAg expression was observed. Furthermore, no upregulation of cytokines and intracellular molecule expression was observed following RP. These data indicate that the immunogenicity of HBV is retained following MP, and the inactivation of HBV could upregulate the Th1‐type cellular immune responses, which may play significant roles in the antiviral process.     

Expression,Purification, and Characterization of Hepatitis B Virus Surface Antigens (HBsAg) in Yeast <Emphasis Type="Italic">Pichia Pastoris</Emphasis>

Prevention of the prevalence of HB depends upon the development of efficient diagnostic reagent and preventive vaccine. Pichia pastoris offers many advantages over the other expression systems in the production of recombinant HBsAg. In this study, we reported that the recombinant P. pastoris strains were cultured in shake flasks and then scaled up in a 5.0-l bioreactor: approximately 27 mg/l of the protein and the maximal cell OD at 600 nm of 310 were achieved in the bioreactor. The recombinant HBsAg was purified by three steps of purification procedures. SDS-PAGE showed that the purified recombinant HBsAg constituted only one homogeneous band of ~24 kDa. CsCl density gradient ultracentrifugation assay indicated that the density of the HBsAg was 1.2 mg/ml, which was in agreement with the natural HBsAg, the HBsAg expressed in Saccharomyces cerevisiae and in mammalian cells. Electron microscope observation revealed that the purified recombinant HBsAg was homogeneous 22-nm particles, suggesting the HBsAg expressed in P. pastoris was self-assembled to virus-like structures. Competitive ELISA indicated that P. pastoris-derived HBsAg possessed the excellent immunoreaction with anti-HBsAg. Animal immunization showed that the immunogenicity of P. pastoris-derived HBsAg was superior to that of S. cerevisiae-derived HBsAg. Together, our results demonstrated that the recombinant HBsAg expressed in P. pastoris could provide promising, inexpensive, and large-scale materials for the diagnostic reagent and vaccine to prevent HBV infection. Electronic supplementary material  The online version of this article (doi:) contains supplementary material, which is available to authorized users. Rushi Liu and Qinlu Lin contributed equally to this work.     

乙型肝炎病毒表面抗原三维结构的同源模建及功能预测

结合生物信息学方法及分子模拟手段, 通过同源模建方法构建了乙型肝炎病毒表面抗原(HBsAg)Pres12的三维空间结构, 并结合生物实验在分子水平上探讨了乙型肝炎病毒表面抗原Pres12作为抗乙型肝炎病毒重要靶标的机理. 研究结果表明, HBsAg三维空间结构是由构型性的Pres1和线性的Pres2组成, 此结构由疏水氨基酸形成3个α-螺旋结构及Loop结构域, 并且N端由Pres1中残基构成了一个开裂, 形成了HBsAg可能的活性部位. 静电势分析结果证实, N端可能的活性部位具有较大的静电势分布, 因而具有与受体细胞蛋白相互作用的能力, 这为HBV病毒抑制剂药物分子的设计提供了有益帮助.     

Virus trap in human serum albumin nanotube

Infectious hepatitis B virus (HBV), namely Dane particles (DPs), consists of a core nucleocapsid including genome DNA covered with an envelope of hepatitis B surface antigen (HBsAg). We report the synthesis, structure, and HBV-trapping capability of multilayered protein nanotubes having an anti-HBsAg antibody (HBsAb) layer as an internal wall. The nanotubes were prepared using an alternating layer-by-layer assembly of human serum albumin (HSA) and oppositely charged poly-L-arginine (PLA) into a nanoporous polycarbonate (PC) membrane (pore size, 400 nm), followed by depositions of poly-L-glutamic acid (PLG) and HBsAb. Subsequent dissolution of the PC template yielded (PLA/HSA)(2)PLA/PLG/HBsAb nanotubes (AbNTs). The SEM measurements revealed the formation of uniform hollow cylinders with a 414 ± 16 nm outer diameter and 59 ± 4 nm wall thickness. In an aqueous medium, the swelled nanotubes captured noninfectious spherical small particles of HBsAg (SPs); the binding constant was 3.5 × 10(7) M(-1). Surprisingly, the amount of genome DNA in the HBV solution (HBsAg-positive plasma or DP-rich solution) decreased dramatically after incubation with the AbNTs (-3.9?log order), which implies that the infectious DPs were completely entrapped into the one-dimensional pore space of the AbNTs.     

化学发光成像法测定人体血清中乙型肝炎病毒

基于对碘苯酚增强的luminol-H2O2-HRP化学发光反应,利用化学发光成像法检测乙肝病毒(HBV)。用该法对人体血清中的乙型肝炎表面抗原、表面抗体、e抗原、e抗体以及核心抗体进行测定,其结果与ELISA法所得结果一致,对表面抗原检测结果为阳性的病人血清测定9次,结果的相对标准偏差为4．2％。     

二氢苯骈[c]菲啶类生物碱的制备及其抗乙肝病毒的活性

二氢苯骈[c]菲啶类生物碱是自然界中一类重要的生物活性成分,但含量很低.利用硼氢化还原方法,对博落回粗提物中的血根碱和白屈菜红碱混合物进行还原、分离,得到了二氢血根碱和二氢白屈菜红碱;并初步评价了其抗乙肝病毒活性.结果表明,利用硼氢化还原方法制备二氢苯骈[c]菲啶类生物碱的产率较高,还原产物具有一定的抗乙肝病毒活性.